Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: Phase II study

Annals of Hematology

Volumn 93, Issue 9, 2014, Pages 1571-1577

  Ahn, Seo Yeon ^a   Jung, Sung Hoon ^a   Joo, Young Don ^b   Lee, Won Sik ^b   Lee, Sang Min ^b   Choi, Chul Won ^c   Kim, Seok Jin ^d   Kim, Kihyun ^d   Lee, Je Jung ^a  

^a Chonnam National University Research Institute of Medical Sciences   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bortezomib; Induction chemotherapy; Multiple myeloma; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; BORTEZOMIB; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MELPHALAN; THALIDOMIDE;

ACUTE HEART INFARCTION; ADULT; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL COUNT; CONSTIPATION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HERPES ZOSTER; HUMAN; INDUCTION CHEMOTHERAPY; INFECTIOUS COMPLICATION; INSOMNIA; LONG TERM SURVIVAL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; MIDDLE AGED; MULTIPLE MYELOMA; NEOADJUVANT THERAPY; PATIENT SELECTION; PYRAZINES; REMISSION INDUCTION; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84905595429     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2067-3     Document Type: Article

References (24)

1. Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883 (Pubitemid 36532313)
2. Koreth J, Cutler CS, Djulbegovic B et al (2007) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 13:183-196 (Pubitemid 46112369)
3. Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91-97 (Pubitemid 26240110)
4. Kristinsson SY, Landgren O, Dickman PW et al (2007) Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from1973 to 2003. J Clin Oncol 25:1993-1999 (Pubitemid 46972782)
5. Brenner H, Gondos A, Pulte D (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111:2521-2526
6. Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520
7. Morgan GJ, Davies FE, Gregory WM et al (2012) Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 97:442-450
8. Yang DH, Kim YK, Sohn SK et al (2010) Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosedmultiplemyeloma: a phase II study. Clin Lymphoma Myeloma Leuk 10:62-67
9. Jung SH, Park H, Ahn JS et al (2013) Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen. Int J Hematol 97:92-97
10. Cavo M, Tacchetti P, Patriarca F et al (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075-2085
11. Buda G, Orciuolo E, Carulli G et al (2013) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients. Acta Haematol 129:35-39
12. Richardson PG, Xie W, Mitsiades C et al (2009) Single-agent bortezomib in previously untreatedmultiplemyeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27:3518-3525
13. Rajkumar SV, Rosinol L, Hussein M et al (2008) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26:2171-2177
14. Lokhorst HM, Schmidt-Wolf I, Sonneveld P et al (2008) Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 93:124-127 (Pubitemid 351156161)
15. Harousseau JL, Attal M, Avet-Loiseau H et al (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 28:4621-4629
16. Nooka AK, Kaufman JL, Behera M et al (2013) Bortezomibcontaining induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer 119:4119-4128
17. Kobayashi T, Kuroda J, Fuchida S et al (2013) The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma. Intern Med 52:961-968
18. Lahuerta JJ, Mateos MV, Martinez-Lopez J et al (2008) Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 26:5775-5782
19. Harousseau JL, Avet-Loiseau H, Attal M et al (2009) Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 27:5720-5726
20. Chanan-Khan AA, Giralt S (2010) Importance of achieving a complete response inmultiplemyeloma, and the impact of novel agents. J Clin Oncol 28:2612-2624
21. O'Shea D, Giles C, Terpos E et al (2006) Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 37:731-737
22. Alegre A, Diaz-Mediavilla J, San-Miguel J et al (1998) Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Hematopoyetico-GETH) and PETHEMA. Bone Marrow Transplant 21:133-140 (Pubitemid 28044005)
23. Alvares CL, Davies FE, Horton C et al (2005) Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratificationmodel can help to direct the use of novel treatments. Br J Haematol 129:607-614 (Pubitemid 40825821)
24. van de Velde HJ, Liu X, Chen G et al (2007) Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92:1399-1406 (Pubitemid 350144158)